Mus vs Panama: HIV-positive TB patients on ART (antiretroviral therapy)
Mus
100.0%
in 2024
Panama
100.0%
in 2024
Mus rank
1st
Panama rank
1st
HIV-positive TB patients on ART (antiretroviral therapy) over time
- Mus
- Panama
How they compare
Mus currently reports 100.0% against 100.0% in Panama, a difference of 0.0%.
The two have swapped places 5 times across 21 shared years of data; in 2004 it was Mus ahead.
Mus ranks 1st and Panama ranks 1st of 2 regions.
Across the 3 decades both report, Mus averaged higher in 2 and Panama in 1.
Head to head by decade
| Decade | Mus | Panama | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 72.8% | 25.0% | 47.8% | Mus |
| 2010s | 86.2% | 95.4% | 9.2% | Panama |
| 2020s | 100.0% | 95.8% | 4.2% | Mus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv-positive tb patients on art (antiretroviral therapy), Mus or Panama?
- Mus, at 100.0% against 100.0% in Panama as of 2024.
- What is the difference in hiv-positive tb patients on art (antiretroviral therapy) between Mus and Panama?
- 0.0%, with Mus ahead.
- How many years of comparable data are there for Mus and Panama?
- 21 years are reported by both, from 2004 to 2024.
- How do Mus and Panama rank globally for hiv-positive tb patients on art (antiretroviral therapy)?
- Mus ranks 1st and Panama ranks 1st of 2 regions.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.